Clinical Trials Logo

Filter by:
NCT ID: NCT00600860 Recruiting - Clinical trials for Myelodysplastic Syndromes (MDS)

A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes

EUMDS
Start date: April 2008
Phase:
Study type: Observational

Study Objectives: To collect and describe demographics, disease-management, and treatment outcomes of Myelodysplastic Syndromes (MDS) patients who are newly diagnosed and classified according to the World Health Organization (WHO) criteria. To perform observational studies concerning relevant scientific research questions in MDS using clinical data and biological samples, and to present relevant research outcomes in the fields of diagnosis and prognostication, health related quality of life issues, health economics, and risk stratification for newly developed classes of drugs. To disseminate results of the studies to all stakeholders involved.

NCT ID: NCT00589537 Recruiting - Clinical trials for Testicular Germ Cell Tumor

Magnetic Resonance Imaging and Computed Tomography in Patients With Stage I Seminoma of the Testicle

Start date: March 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: Imaging procedures, such as MRI and CT scan, may find recurrent cancer. It is not yet known which MRI or CT scan schedule is more effective in finding recurrent cancer. PURPOSE: This randomized phase III trial is comparing four different MRI and CT scan schedules in patients with stage I seminoma of the testicle.

NCT ID: NCT00562068 Recruiting - Lymphoma Clinical Trials

Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma

Start date: May 2007
Phase: Phase 1
Study type: Interventional

RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from growing. Giving alemtuzumab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of alemtuzumab when given together with combination chemotherapy and to see how well it works in treating patients with stage I , stage II , stage III, or stage IV peripheral T-cell lymphoma.

NCT ID: NCT00560365 Recruiting - Colorectal Cancer Clinical Trials

Follow-Up Study of Patients Who Have Undergone Surgery for Stage I, Stage II, or Stage III Colorectal Cancer

Start date: March 2004
Phase: N/A
Study type: Observational

RATIONALE: Following patients who have undergone surgery for colorectal cancer may help doctors learn more about the disease and plan better follow-up care. PURPOSE: This randomized clinical trial is following patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer.

NCT ID: NCT00553566 Recruiting - Bladder Cancer Clinical Trials

Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer

Start date: December 2005
Phase: Phase 3
Study type: Observational

RATIONALE: Learning about the long-term effects of dietary, lifestyle, and environmental factors on the risk of cancer progression and recurrence may help the study of bladder cancer in the future. PURPOSE: This clinical trial is studying how dietary, lifestyle, and environmental factors affect patients with early-stage bladder cancer.

NCT ID: NCT00553371 Recruiting - Clinical trials for Testicular Germ Cell Tumor

Follow-up Evaluation Using CT Scans in Patients Who Have Been Treated For Metastatic Testicular Cancer

Start date: April 2006
Phase: N/A
Study type: Observational

RATIONALE: Learning about long-term effects in patients with testicular cancer may help doctors plan better treatment and follow-up care. PURPOSE: This clinical trial is using CT scans to follow patients who have been treated for metastatic testicular cancer.

NCT ID: NCT00553345 Recruiting - Bladder Cancer Clinical Trials

Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer

Start date: December 2005
Phase: Phase 3
Study type: Interventional

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of selenium and vitamin E may stop cancer from growing or coming back. PURPOSE: This randomized phase III trial is studying giving selenium together with vitamin E to see how well it works compared with a placebo in preventing cancer progression and recurrence in patients with early-stage bladder cancer.

NCT ID: NCT00553215 Recruiting - Bladder Cancer Clinical Trials

Quality of Life in Patients With Bladder Cancer

Start date: December 2005
Phase: Phase 3
Study type: Observational

RATIONALE: Studying quality of life in patients with bladder cancer may help determine the long-term effects of bladder cancer and may help improve the quality of life for patients in the future. PURPOSE: This clinical trial is studying quality of life in patients with bladder cancer.

NCT ID: NCT00553124 Recruiting - Bladder Cancer Clinical Trials

Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer

Start date: December 2005
Phase: Phase 3
Study type: Interventional

RATIONALE: Studying different factors that effect patients with newly diagnosed bladder cancer may help doctors learn more about the disease, improve the ability to plan cancer treatment, and help patients live more comfortably. PURPOSE: This clinical trial is studying different factors affecting patients with newly diagnosed bladder cancer.

NCT ID: NCT00551122 Recruiting - Ovarian Cancer Clinical Trials

Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors

GemTIP
Start date: November 2006
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, paclitaxel, ifosfamide, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of gemcitabine when given together with paclitaxel, ifosfamide, and cisplatin, and to see how well they work in treating patients with progressive or relapsed metastatic germ cell tumors.